Business Standard

Monday, December 23, 2024 | 06:25 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Glenmark receives USFDA approval for Clindamycin Phosphate Foam, 1%

Image

Capital Market
Glenmark Pharmaceuticals has received final approval by the United States Food & Drug Administration (USFDA) for Clindamycin Phosphate Foam, 1%, the generic version of Evoclin1 Foam, 1%, of Mylan Pharmaceuticals Inc.

According to IQVIATM sales data for the 12 month period ending July 2021, the Evoclin Foam, 1%, market achieved annual sales of approximately $12.0 million.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Sep 21 2021 | 9:06 AM IST

Explore News